Mechanism for distribution of acotiamide, a novel gastroprokinetic agent for the treatment of functional dyspepsia, in rat stomach

Journal of Pharmaceutical Sciences

Volumn 100, Issue 11, 2011, Pages 4965-4973

  Yoshii, Kazuyoshi ^a   Hirayama, Masamichi ^a   Nakamura, Toshifumi ^a   Toda, Ryoko ^a   Hasegawa, Junko ^a   Takei, Mineo ^a   Mera, Yukinori ^a   Kawabata, Yoshihiro ^a  

^a ZERIA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Active transport; Distribution; Facilitated diffusion transport; Functional dyspepsia; Gastrointestinal; Protein binding

Indexed keywords

ACOTIAMIDE; ID 951551; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; DRUG UPTAKE; DYSPEPSIA; MALE; NONHUMAN; RAT; SKELETAL MUSCLE; STEADY STATE; STOMACH;

EID: 80053275589     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22649     Document Type: Article

References (18)

1. Tack J, Masclee A, Heading R, Berstad A, Piessevaux H, Popiela T, Vandenberghe A, Kato H. 2009. A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia. Neurogastroenterol Motil 21:272-280.
2. Matsunaga Y, Tanaka T, Yoshinaga K, Ueki S, Hori Y, Eta R, Kawabata Y, Yoshii K, Yoshida K, Matsumura T, Furuta S, Takei M, Tack J, Itoh Z. 2011. Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: Comparison with cisapride, itopride, and mosapride. J Pharmacol Exp Ther 336:791-800.
3. Matsunaga Y, Ueki S, Matsumura T, Nomura Y, Yoneta T, Kurimoto T, Tamaki H, Itoh Z. 1998. Z-338, a novel gastroprokinetic agent stimulates gastrointestinal motor activity and improves delayed gastric emptying in the dog and rat. Jpn J Pharmacol 76(Suppl 1):290.
4. Romi F, Gilhus NE, Aarli JA. 2005. Myasthenia gravis: Clinical, immunological, and therapeutic advances. Acta Neurol Scand 111:134-141.
5. Zheng HL, Hu YM, Bao JJ, Xu JM. 2010. Transfer and distribution of amoxicillin in the rat gastric mucosa and gastric juice and the effects of rabeprazole. Acta Pharmacol Sin 31:501-508.
6. Summerfield SG, Read K, Begley DJ, Obradovic T, Hidalgo IJ, Coggon S, Lewis AV, Porter RA, Jeffrey P. 2007. Central nervous system drug disposition: The relationship between in situ brain permeability and brain free fraction. J Pharmacol Exp Ther 322:205-213.
7. Kim DC, Sugiyama Y, Satoh H, Fuwa T, Iga T, Hanano M. 1988. Kinetic analysis of in vivo receptor-dependent binding of human epidermal growth factor by rat tissues. J Pharm Sci 77:200-207.
8. Liu KX, Kato Y, Narukawa M, Kim DC, Hanano M, Higuchi O, Nakamura T, Sugiyama Y. 1992. Importance of the liver in plasma clearance of hepatocyte growth factors in rats. Am J Physiol 263:G642-G649.
9. Wilkinson GR, Shand DG. 1975. Commentary: A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-390.
10. Pang KS, Rowland M. 1977. Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625-653.
11. Hosseini-Yeganeh M, McLachlan AJ. 2002. Physiologically based pharmacokinetic model for terbinafine in rats and humans. Antimicrob Agents Chemother 46:2219-2228.
12. Wierzba K, Sugiyama Y, Okudaira K, Iga T, Hanano M. 1987. Tubulin as a major determinant of tissue distribution of vincristine. J Pharm Sci 76:872-875.
13. Jonker JW, Wagenaar E, Mol CA, Buitelaar M, Koepsell H, Smit JW, Schinkel AH. 2001. Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol Cell Biol 21:5471-5477.
14. Okuda M, Saito H, Urakami Y, Takano M, Inui K. 1996. cDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2. Biochem Biophys Res Commun 224:500-507.
15. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y. 2002. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 302:510-515.
16. Furuta S, Kamada E, Omata T, Sugimoto T, Kawabata Y, Yonezawa K, Wu XC, Kurimoto T. 2004. Drug-drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadine, comparison with cisapride, and involvement of UGT1A9 and 1A8 in the human metabolism of Z-338. Eur J Pharmacol 497:223-231.
17. Grams B, Harms A, Braun S, Strassburg CP, Manns MP, Obermayer-Straub P. 2000. Distribution and inducibility by 3-methylcholanthrene of family 1 UDP-glucuronosyltransferases in the rat gastrointestinal tract. Arch Biochem Biophys 377:255-265.
18. Shelby MK, Cherrington NJ, Vansell NR, Klaassen CD. 2003. Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family. Drug Metab Dispos 31:326-333.